课题基金 / 基金详情

LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes

LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes
LIVOPT——肝硬化——优化患者结果的预测
批准号:
10666608
负责人:
Daniela P Ladner
金额:
$60.23万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-30 至 2026-05-31

项目摘要

项目成果

Daniela P Ladner的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT Cirrhosis is a leading cause of mortality in the United States (US), diagnosed in millions of people and resulting in over 40,000 deaths each year, predominately in older people. These patients are at higher risk of serious complications (e.g. infection, ascites, hepatic encephalopathy), hospitalization and death. Little is known about the epidemiology and disease progression and older patients are more vulnerable and might have different risk profiles. The clinical challenge is to accurately and early predict who is at highest risk for requiring hospitalization and/or death and understanding how this might be different in older versus younger adults. . One barrier to date has been the lack of an epidemiologically representative patient sample that captures those with cirrhosis and goes beyond one health system, as many data repositories are skewed or limited: CMS only captures elderly and those with debility, NIS does not allow longitudinal observation, UNOS represents less than one percent of those with cirrhosis. Hence, we will build on our previous work to use a unique dataset, the Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN). CAPriCORN captures the electronic health records (EHR) from nine health systems from 2011-present (incl. academic center, county, VA and private), catching most of the diverse patient population in the greater Chicago metropolitan area, namely ~160,000 patients with liver cirrhosis. The dataset is extensive, allowing the use of traditional (e.g., regression) and novel analytical techniques (e.g. deep learning) to pursue the aims of the study. We aim to model cirrhosis progression in the elderly and to predict the risk of hospitalization and death in older patients with cirrhosis. We also aim to perform sub-group analyses focusing on race and socioeconomic factors in the elderly. The impact of accurate and early prediction of mortality and hospitalization risk in elderly patients with cirrhosis allows for targeted interventions of the most vulnerable patients to improve outcomes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Natural history, risk prediction and cost of cirrhosis in insured Americans.
Natural history, risk prediction and cost of cirrhosis in insured Americans.
The Northwestern Summer Research Program for Medical Students
LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: